Effectiveness of Botulinum Toxin Type A for Trichodynia Associated with Hair Loss Disorders: A Retrospective Study - Report - MDSpire

Effectiveness of Botulinum Toxin Type A for Trichodynia Associated with Hair Loss Disorders: A Retrospective Study

  • By

  • David Saceda-Corralo

  • Adrián Imbernon-Moya

  • Juan Jiménez-Cauhe

  • Cristina Pindado-Ortega

  • Valentina Balaguera-Orjuela

  • Patricia Burgos-Blasco

  • Amparo Guillem

  • Rocío Gil-Redondo

  • Sergio Vañó-Galván

  • June 24, 2026

  • 0 min

Share

Clinical Report: Efficacy of Botulinum Toxin Type A in Managing Trichodynia

Overview

Intradermal botulinum toxin type A (BTA) has shown rapid and sustained reduction in trichodynia severity among patients with cicatricial alopecias.

Background

Trichodynia is a painful scalp sensation linked to various alopecia types, significantly affecting patients' quality of life and contributing to psychological issues. Conventional treatments are often inconsistent.

Data Highlights

No specific numerical data or trial results were provided in the source material.

Key Findings

  • Intradermal BTA demonstrated significant reduction in trichodynia severity.
  • Patients with cicatricial alopecias experienced rapid and sustained relief from symptoms.
  • BTA treatment resulted in minimal adverse effects.
  • Conventional treatments for trichodynia often yield inconsistent results.
  • Trichodynia is associated with impaired quality of life and psychological comorbidities.

Clinical Implications

The findings suggest that BTA may be a viable treatment option for patients suffering from trichodynia, particularly those who have not responded to conventional therapies. Clinicians should consider BTA as part of a comprehensive management strategy for affected patients.

Conclusion

The study supports the use of intradermal BTA as an effective treatment for trichodynia, indicating its potential role in improving patient outcomes in hair loss conditions.

Related Resources & Content

  1. Faris A. Alhomida, Frontiers in Psychiatry, 2026 -- Beyond aesthetic outcomes: psychodermatological benefits of botulinum toxin treatment in the upper facial third. A narrative review
  2. Frontiers in Pain Research, 2026 -- Add-on benefits of botulinum toxin type A in combination or sequential therapies for scar management: a systematic review and meta-analysis
  3. Clinical Rheumatology, 2024 -- A comprehensive review of the efficacy of botulinum toxin in managing Raynaud's phenomenon associated with scleroderma
  4. British Association of Dermatologists, 2024 -- Living guideline for managing people with alopecia areata
  5. Frontiers in Neurology — Intervention effects of different brands of botulinum toxin type A on Meige syndrome with anxiety symptoms
  6. British Association of Dermatologists living guideline for managing people with alopecia areata 2024 | British Journal of Dermatology | Oxford Academic
  7. Effects and Safety of Botulinum Toxin Injection in Treatment of Androgenetic Alopecia: A Meta-analysis and Systematic Review - PubMed
  8. The presence of trichodynia in patients with telogen effluvium and androgenetic alopecia - PubMed

Original Source(s)

Effectiveness of Botulinum Toxin Type A for Trichodynia Associated with Hair Loss Disorders: A Retrospective Study

  • by David Saceda-Corralo, Adrián Imbernon-Moya, Juan Jiménez-Cauhe, Cristina Pindado-Ortega, Valentina Balaguera-Orjuela, Patricia Burgos-Blasco, Amparo Guillem, Rocío Gil-Redondo, Sergio Vañó-Galván

  • June 24, 2026

Related Content

Editorial: Rethinking infection in pediatric atopic dermatitis: from microbial dysbiosis to precision prevention

Efficacy and Safety of a Topical Skincare Regimen with Tripeptide/Hexapeptide following Aesthetic Procedures: Analysis of Two Randomized, Split-Face Trials in Asian Subjects

Clinical and imaging features of tufted angioma in children